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Abstract  
Objectives:  1) To use data-driven method to examine clinical codes (risk factors) of a medical condition in primary 
care electronic health records (EHRs) that can accurately predict a diagnosis of the condition in secondary care EHRs. 
2) To develop and validate a disease phenotyping algorithm  for rheumatoid arthritis using primary care EHRs.  
Methods: This study linked routine primary and secondary care EHRs in Wales, UK. A machine learning based 
scheme was used to identify patients with rheumatoid arthritis from primary care EHRs via the following steps: i) 
selection of variables by comparing relative frequencies of Read codes in the primary care dataset associated with 
disease case compared to non-disease control (disease/non-disease based on the secondary care diagnosis); ii) 
reduction of predictors/associated variables using a Random Forest method, iii) induction of decision rules from 
decision tree model. The proposed method was then extensively validated on an independent dataset, and compared 
for performance with two existing deterministic algorithms for RA which had been developed using expert clinical 
knowledge.    
Results: Primary care EHRs were available for 2,238,360 patients over the age of 16 and of these 20,667 were also 
linked in the secondary care rheumatology clinical system.  In the linked dataset, 900 predictors (out of a total of 
43,100 variables) in the primary care record were discovered more frequently in those with versus those without RA. 
These variables were reduced to 37 groups of related clinical codes, which were used to develop a decision tree 
model. The final algorithm identified 8 predictors related to diagnostic codes for RA, medication codes, such as those 
for disease modifying anti-rheumatic drugs, and absence of alternative diagnoses such as psoriatic arthritis. The 
proposed data-driven method performed as well as the expert clinical knowledge based methods.     
Conclusion:  Data-driven scheme, such as ensemble machine learning methods, has the potential of identifying the 
most informative predictors in a cost-effective and rapid way to accurately and reliably classify rheumatoid arthritis 
or other complex medical conditions in primary care EHRs. 
Key words:  Disease phenotyping; rheumatoid arthritis, primary care; routine data; machine learning. 
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Background 
Rheumatoid arthritis (RA) is the most common chronic inflammatory arthritis worldwide. It affects approximately 
1% of the population in countries like the UK [1] and USA [2], with significant morbidity and increased mortality. 
Most RA clinical trials capture relatively short-term data in small numbers of patients, while longer trials are costly 
and time-consuming, with difficulty maintaining the levels of follow up required to evaluate the important long-term 
outcomes in this chronic, life-long disease. Emerging studies have shown that patient recruitment for clinical trials 
and follow up from trials could be significantly improved by use of electronic health records [3][4][5][6]. But a key 
requirement is the accurate and reliable identification of patients who satisfy the RA criteria from electronic health 
records. 
Indeed, in this age of big data, large quantities of real time data from national and regional population datasets 
can be accessed and utilised to gain knowledge on the entire population rather than extrapolating from a single 
sample. It is now possible to examine a patient’s journey through the healthcare system by linking their electronic 
health records [7,8]. One can examine information on first symptoms, tests/results, referrals, diagnosis, and 
prescriptions for all patients with a condition in the region or country, providing an unparalleled opportunity to 
study disease in a real world setting.  This offers the chance for real time surveillance of disease history, co-
morbidities and long term treatment effects in patients with chronic diseases, such as RA. However, since the 
introduction of biologic therapies, patients with RA are generally diagnosed and managed in specialist rheumatology 
centres, with relatively limited input from primary care physicians. As such, secondary care electronic health records 
contain more robust RA-related diagnostic data than primary care records, but these records are sparse, cover far 
smaller patient numbers, often contain only severe active disease and are not easily available. This leads to only 
identifying patients with RA in that specific rheumatology secondary care setting, thereby introducing bias and 
limiting generalizability.  In contrast, primary care data is more widely available containing a much broader spectrum 
of patient care codes including details of a patient’s diagnoses, medications, managements and health outcomes and 
information on demographic variables and co-morbidies.  But, in primary care EHRs , the non-specific diagnosis of 
‘arthritis’ can be used for people who have other conditions like osteoarthritis, ankylosing spondylitis or non-specific 
joint pain [9] meaning that some conditions may appear under-reported in primary care while others over-reported. 
So accurately and reliably identifying patients with RA from primary care database remains challenging, and usually 
requires a combination of evidence from diagnosis, medication, treatment and investigation codes [10,11]. Existing 
algorithms to identify RA from primary care records are based on manual selection of the most relevant  codes [12]. 
Thomas et al ’s method [12] is based on codes chosen manually by clinical experts, while the other method [13] is 
based on the codes used by the Quality and Outcomes Framework (QOF), a pay for performance scheme in which a 
standardised set of clinician-selected codes is used to determine the prevalence of a condition (in this case RA) in a 
practice. However, the methodology of manual selection of relevant codes based on expert knowledge is very 
subjective and depends on the health care system of the area and what clinicians (often secondary care physicians) 
think should be found in the primary care record.  
An alternative is to use secondary care diagnosis as a gold standard and examine which health-related codes in 
the primary care dataset are predictive of a secondary care diagnosis. That leads to patterns found in the primary 
care records can be used to predict the presence or absence of the RA in secondary care specialist data. This means 
RA can be reliably identified using primary care records in the absence of access to secondary care specialist records. 
But identifying these patterns is not straightforward, because the criteria which characterise the RA are buried within 
complex hierarchical terminology structures across multiple data points in the electronic health records of a patient, 
such as the Read codes (5 bytes, Version 3)[14] developed by the National Health Service of the United Kingdom 
(NHS), or the SNOMED CT (Systematized Nomenclature of Medicine Clinical Terms) that merges two large-scale 
terminologies – the Read codes and the SNOMED Reference terminologies developed by the College of American 
Pathologists[15]. In particular, recording practices with these terminologies vary substantially across healthcare 
settings depending on the purpose for which the data are being collected. As a result, a huge number of health-related 
variables (codes) often turn up to describe the conditions of a patient across multiple data points. This presents a big 
methodological challenge for identifying patients from electronic health records, as the high dimensionality of health-
related features makes the classical statistical framework no longer feasible due to the curse of dimensionality 
[10,11][16][17]. Thus, to reliably distinguish RA patients from electronic health records, the key is to identify the 
most predictive RA code patterns buried in the electronic health records.  
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In this study, we aim to develop a robust, valid and cost-effective method of identifying the most informative 
predictors to detect RA patients from primary care electronic health records. Different from a purely knowledge 
driven and deterministic approach, in this study, we propose to use data-driven method, which were initially used in 
the computing and retail industries (e.g., looking at shopping patterns for marketing) [18], to identify patterns within 
the patient’s pathway of care to improve the accuracy of identification of those with RA from the primary care record. 
We link primary and secondary care electronic patient records, and identify patients with RA in the primary care 
dataset while using the secondary care diagnosis as the gold standard. Then we compare our data-driven 
methodology with two other existing expert knowledge based methods. If the data driven method performs as well as 
expert opinion, then it could provide a rapid and cost-effective way to reliably identify people with a health condition, 
especially where knowledge-driven algorithms do not already exist. Thus, the overall aim of this study was to develop 
an algorithm to define RA from primary care records using data driven method. 
Methods 
Dataset preparations 
The Farr Institute of Health Informatics Research comprises four centres distributed across the UK. One of the nodes, 
CIPHER (Centre for Improvement in Population Health through E-Records), brings together routine health data using 
the Secure Anonymised Information Linkage (SAIL) databank [19], which anonymously links a wide range of person-
based data employing a unique personal identifier [20]. In this study the primary care general practice (GP) records 
were linked with the local rheumatology secondary care clinical system. The GP system uses Read codes, which are 5-
digit codes that relate to diagnosis, medication and process of care.   
The structure of Read codes allows almost anything to be coded in the patient EHRs, such as occupation; social 
circumstances; ethnicity and religion; clinical signs, symptoms and observations; laboratory tests and results; 
diagnoses; medications; a variety of administrative items.  Read terms are organised by Chapters, such as Chapters 1 
to 9 about  history, examination, procedures and administration, Chapters A to U about conditions, diagnoses and 
injuries, and Chapters a to s about medications.  
The secondary care dataset used in this study is from the clinical system - Cellma [21] which has been used in the 
rheumatology departments of local hospitals in Abertawe Bro Morgannwg University (ABMU – Swansea and 
Bridgend areas) and Cardiff and Vale University Health Board (CVUHB). This commercial system uses SNOMED-CT to 
code diagnosis and medications [22] as well as recording clinical data entered by rheumatologists at the point of 
capture. The Cellma systems were available in the ABMU region from March 2009 until October 2012, and in Cardiff 
from October 2013 to July 2014. Hospital admissions data for the whole population of Wales is available in the SAIL 
databank, along with data from all general practices in the ABMU region and 50% of general practices in the Cardiff 
region.  
There were 2,238,360 patients over the age of 16 in the GP database contained in the SAIL databank between the 
years 1999-2013. Linking the general practice and Cellma databases gave an overlap of 20,667 people (15,459 from 
ABMU for 2009-2012 and 5,208 from Cardiff for 2013 -2014). The proportion of patients with a diagnosis of RA, 
according to specialist rheumatologist consultants, recorded in Cellma (used as the gold standard diagnosis) was 
17% (n=2,588 overall, 2,029 in the ABMU region and 559 in the Cardiff region).  
Analysis methods 
Development of the data driven algorithm 
Due to the higher number of patients with RA in ABMU, this area was used to develop the algorithm as outlined 
below. Then the Cardiff dataset was used as an independent population to validate the algorithm. 
Phase 1: Preliminary selection of predictors 
Due to the large number of codes available in the UK primary care system, a preliminary selection of codes associated 
with RA was needed. This involved examination of the relative frequencies of raw Read codes in those with gold 
standard Cellma diagnosis of RA (cases) versus all those without RA (controls), which is defined as follows 
𝑟𝐹𝑒𝑞(𝑥) = 𝑝(𝑅𝐴|𝑥) − 𝑝(𝑛𝑜𝑛𝑅𝐴|𝑥) 
where 𝑝(𝑅𝐴|𝑥) = 𝑁𝑥.1 𝑁⁄  and 𝑝(𝑛𝑜𝑛𝑅𝐴|𝑥) = 𝑁𝑥.2 𝑁⁄  are the prior probabilities of the RA and non-RA cases 
respectively given the Read code x with Nx.1 cases of RA and Nx.2 cases of non-RA among all N patients. In ranking the 
5 
 
Read codes, the defined relative frequency allows important but infrequent Read codes to be identified. For example, 
the code for ‘swollen hand’ may be rare in the entire database but 10 times more prevalent in RA patients. All the 
Read codes with a higher relative frequency in cases versus controls were selected as initial predictor variables. 
However, in this phase, the proposed relative frequency is a univariate metric only used to measure the significance 
of a single risk factor, without considering the interactions between different factors.   
Phase 2: Reduction of predictors through aggregation and wrapper approach 
In this phase, in order to select important subset of variables and taking into account the interactions among 
variables, a feature selection wrapper approach was employed to perform feature selection and classification tasks 
simultaneously. Random Forest was used to rank the importance of individual predictors and select key ones. 
Random Forest is an ensemble machine learning classifier consisting of many local classification and regression tree 
classifiers [23]. In our study, we used the Random Forest Gini impurity metric to rank the Read codes according to 
which were most useful in correctly classifying cases versus controls. The Gini quantity gives an indication of how 
strong the overall discriminative ability of a particular variable was for the classification problem under study. 
Importantly, the “grouping property” of sub-trees [24] enables the Random Forest to adeptly deal with correlation 
and interaction among variables. Emerging evidence has shown that ranked variables considering the correlation and 
interaction effects lead to a vast improvement for construction of a compact classification model [25]. The Random 
Forest method selects two thirds of the data to construct each of the trees and then employs the remaining one third 
of the data to estimate how many people are misclassified.  For example, one tree might be: If code for RA and code for 
methotrexate are present then identify these records as RA (case). Then the final one third split data can be used to see 
how often this tree correctly classifies a person. It performs this for all trees and then, generates a list of predictors 
ordered by their importance.  
After ranking, an aggregation method was used to aggregate these selected Read codes if they were similar to 
others in the database. For example, some medication Read codes, such as those related to vitamin D prescription at a 
specific dose, were found among the list of selected predictors. Read codes for vitamin D at differing doses (perhaps 
less frequently prescribed but still valid predictors) can then be selected and examined to see if they improve the 
number of people correctly classified. This means that the list of initial predictors acts like a list of ‘seeds’ to identify 
similar variables in the database. The variables sharing the same condition can be further aggregated into one 
variable (e.g., grouping codes for laboratory tests that are normally performed together, such as Read codes for white 
blood cell count to include basophil count, lymphocyte count, eosinophil count, neutrophil count, and monocyte 
count). Although the Random Forest method constructed numerous possible trees that perform well in selecting 
important predictors to classify patients as either RA or non-RA, it is a “black-box” method in nature, as it is difficult 
to induce the transparent classification rules and interpret the predictions made by the model.   
Phase 3: Classification rule induction 
During this phase, the C5.0 decision tree (an improved version of C4.5) [26] was used to automatically create ‘if-then’ 
rules using the aggregated and selected predictors from the previous phases. Distinct from other machine learning 
techniques, decision trees integrate the functions of the classification and feature selection in one model structure. 
The C5.0 decision tree method uses a single tree/model to classify patients, while the ‘if-then’ statements generated 
by a tree define a unique route to one terminal node (RA or not RA) for any samples. For example, if a diagnosis of PsA 
(Psoriatic Arthritis) was recorded, then the result would be ‘not RA’. If there was no diagnosis of PsA, then the algorithm 
would advance to the next section of the tree. Each branch gives a single rule. This hierarchical structure leads to many 
rules sharing the same initial conditions, which constructs an algorithm of identifying RA. 
Validation of the algorithm 
The algorithm was then applied to two datasets: (a) the independent Cardiff dataset of patients with a GP and 
secondary care rheumatology record, to evaluate performance at classifying RA among those attending a 
rheumatology clinic; and (b) all 475,580 people in the GP system and resident within the ABMU area during the 
period March 2009 to October 2012 (this is the period when there are valid diagnosis of conditions within the ABMU 
Cellma) and aged 16+ during this time period. The performance of the algorithm in the Cardiff dataset was assessed 
by calculating the sensitivity, specificity and positive predictive value and compared with the performance of two 
existing algorithms which were generated based on expert clinical opinion. These two existing algorithms were (1) 
the Quality and Outcomes Framework (QOF) definition [13], and (2) the algorithm published by Thomas et al. [12], 
which was developed on data from GP systems in England and so comparable to data systems in Wales. (The codes 
used by the QOF criteria and Thomas et al’s method in this study can be found in the Supplementary Table). In terms 
of dataset (b) we reported sensitivity, specificity and positive predictive value using a best case/worst case scenario 
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analysis (Table 1). We also examined the prevalence of RA over time using these algorithms in dataset (b) to confirm 
that estimates were within the range expected from the literature.  
Statistical analysis 
The algorithm implementation, parameter tuning and performance evaluation were all performed using R language 
in RStudio version 3.0.2 [27] with the packages of ‘randomForest’ for RF [28],  and ‘C50’ for C5.0 trees [29]. The 
performance of the algorithm was assessed in terms of the sensitivity, specificity and positive predictive value.  
Results 
Algorithm development 
a. Phase 1: 900 predictor codes were identified from 43,100 potential Read codes. These included different 
codes identifying, for example, the same medication but at varying doses or varying administration methods 
(tablet, syrup, injection). These similar codes were aggregated in the next phase.  
b. Phase 2: The 900 predictors were reduced to 37 predictor code groups after the aggregation phase.  The 37 
predictor code groups included groups of codes under a single name (for example the code of 
‘PREDNISOLONE’ would include all codes with Prednisolone listed as the active ingredient, including the 
Read code for PREDNISOLONE 2.5 mg e/c tablets and the code for PREDNISOLONE  5mg e/c tablets).  
c. Phase 3: A C5.0 decision tree was generated to identify RA patients. The C5.0 tree further reduced the 37 
predictor code groups to 8 predictor code groups. The decision tree method helps to remove codes which 
cluster with other more predictive codes, accounting for covariance and allowing the simplest model to be 
identified with the highest positive predictive value in the Welsh population (see Figure 1). The 8 predictor 
code groups for the Welsh population were: (1) RA codes as defined in the NHS QOF indictor set,  (2) a 
group of codes indicating strength of evidence for RA (including codes for seropositive or erosive RA and 
codes for systemic manifestations of RA, see Table 2 for details), (3) a group of psoriatic arthritis Read codes 
used to exclude RA; (4) an additional group of alternative diagnosis codes for arthropathies other than RA 
or PsA also used to exclude RA as a diagnosis, (5) prednisolone (at all different dosage), (6) methotrexate 
(all Disease-Modifying Antirheumatic Drugs (DMARD) with the active ingredient listed as methotrexate), (7) 
sulphasalazine and (8) leflunomide.  
 
The decision rules with these predictor codes were induced as shown in Figure 1.  
Algorithm validation 
Secondary care/GP overlap population in Cardiff 
The population used for the validation (Cardiff-Cellma) had 27 % prevalence of RA. The data driven algorithm gave a 
PPV: 85.6 %, specificity: 94.6%, sensitivity: 86.2 % and overall accuracy of 92.29 %.  This compared with the QOF 
criteria alone (which is included within the data driven algorithm) which gave PPV: 83 %, specificity: 93.2 %, 
sensitivity: 89.1 % and accuracy: 92 %. The Thomas et al’s method gave PPV: 78.5 %, specificity: 91.1 %, sensitivity: 
86.2 % and accuracy: 89.8 %. 
Primary care population  
Of the 475,580 people over 16 years old in the GP system in the ABMU area, the algorithm would have classified 
4,279 (0.9 %) as having RA, which is consistent with an existing study of estimated prevalence of RA  across the UK 
population (0.8-0.9%) [1]. Of the 4,279 people, 1,719 (40%) were found in the secondary care rheumatology system 
and 1,323 (77 %) were confirmed as having RA by the rheumatologist. However, 2,560 (60 %) of all the RA cases in 
the GP data were not found in the secondary care system.  This could be because (a) they did not have RA, (b) they 
are treated outside the ABMU area, such as elsewhere in Wales or in England, (c) they are new cases waiting for a 
referral to the rheumatologist, or (d) they are old cases and no longer regularly seeing a rheumatologist or did not see 
a rheumatologist in the time period for which we have data.  If we assume a worst case scenario, that none of the 
2,560 cases have RA then this would give a prevalence of RA of 0.33 %, a PPV: 30.9 %, specificity: 99 %, sensitivity 83 
%. If we assume a best case scenario, that all of the 2,560 cases did have RA but were treated by a rheumatologist 
outside the area then this estimate would give a RA prevalence of 0.93 %, with PPV: 91.3 %, specificity: 99.9 %, and 
sensitivity 94 %. Plotting the prevalence of RA within the ABMU region over time (Figure 2) shows that the data-
driven model and QOF algorithm produced comparable results, while the Thomas et al criteria gave a lower 
prevalence for the region. 
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Discussion 
EHRs have been considered as an essential component in delivering high quality healthcare. They provide enormous 
benefits not only for patient care, but also, when linked with other sources of health-related records, for public health 
surveillance, measurement of outcomes and a wide variety of research studies[16][17][30][31]. However, it is 
recognised that there are large variations in the accuracy and completeness of the clinical information stored in 
primary care electronic patient records[32][33]. Issues in using primary care electronic patient data include: the 
codes are not robust enough; data curation was not performed resulting in a disconnection between data elements in 
the record and the patient's clinical status; and clinicians may fail to enter codes properly, particularly where these 
relate to conditions diagnosed predominantly in secondary care settings. Therefore, it is unclear whether current 
primary care electronic patient records capture clinical data adequately to reliably identify patients with a particular 
condition for research purposes. In this study, we link primary care records with secondary care records, using the 
secondary care data acting as gold standard diagnosis for RA, to develop a rapid data-driven method which can be 
used to accurately identify patients with RA in primary care data codes. The developed algorithm performed as well 
as expert opinion and the used QOF criteria in the UK.  It demonstrates a method of deriving algorithms which can be 
used for conditions without having QOF criteria and could be extended to develop algorithms on systems that do not 
use Read codes. This data-driven method is based on the RA patient pathway found in the health care system so can 
be used to derive algorithms specific for that system. The findings demonstrate that for RA the QOF is a reliable and 
easy way of identifying a condition. Therefore, when deriving algorithms, looking at the QOF criteria may be the best 
place to start in the UK NHS.  This finding may also be true in other countries where coding is linked to financial 
payments as there may be less variance around these codes [34]. However, the UK QOF criteria only apply to a 
limited number of conditions, while many countries do not have robust coding linked to financial payment. In these 
cases, the data driven method described here is a reliable way to identify codes related to RA.     
The algorithm derived here relies on medication codes which improves the positive predictive value, but reduces 
sensitivity and importantly will mainly select patients with a longer history of the RA condition (who will have had 
time to be given different types of medication) and more severe disease (requiring more therapies). Previous studies 
have also reported that adding codes for DMARDs from administration ICD billing data increases positive predictive 
value in classifying RA patients, but decreases sensitivity [35][36]. Therefore, medication codes can feature highly in 
a prevalence algorithm but an incidence algorithm may need to focus more strongly on tests/procedures and 
ensuring no alternative diagnosis. Thus, distinct algorithms to define prevalent and incident cases may be required.  
This study offers several advantages. 1) It provides a novel way of automatically selecting the most informative 
variables for RA diagnosis from a large number of coded data elements. This can bring benefits in health informatics, 
for example, reducing the costs from many aspects, such as model construction, data usages; using only the most 
informative variables can also simplify the problem and speed up solutions; by selecting only the most informative 
variables, it is feasible to employ a particular classification model due to the challenge of curse of dimensionality; in 
addition, discarding the irrelevant features can clean data and remove the noises to significantly improve the 
generalisation performance by avoiding over-fitting dilemma. 2) It can be performed very rapidly and cost-effectively 
and is particularly useful in situations where it is unclear what RA codes should be used in the case of heterogeneous 
or complex conditions. 3) The proposed method uses real life patient pathways to classify RA rather than idealised 
best practice. 4) The RA decision rules generated are easily understood by users and clinicians in practical 
applications. It is a transparent method, which gives objective results and is repeatable, so that all data and the 
method constructed can themselves lead to reproducible research (datasets and methods can be published to be 
independently analysed).   
However, the method we used requires a gold standard in order to develop or train the model.  There has to be a 
‘correctly diagnosed’ reference in order to detect the patterns that predict that reference. In health informatics 
research, a key limitation in any algorithm development research is the lack of a population based gold standard and 
without this, obtaining a good estimate of performance of models applied to the whole population is difficult. This is 
illustrated by the broad range of possible performance statistics for our RA algorithm when worst and best case 
scenarios are considered.  In addition, this data-driven method is mainly applicable when using coded clinical terms 
and may not be applicable to textual data from notes and letters, as these will require prior interpretation in order to 
be able to detect patterns.    
Regarding implications for future research and practice, while manual selection based methods may achieve good 
predictive performance in patient phenotype identification for specific disease, they require significant interactions 
between domain experts and informaticians to create algorithms for each disease, which significantly limits their 
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ability to be expanded to different disease phenotypes. The data-driven approach in this study aimed at identifying 
the most informative clinical criteria from data independently of domain experts (and the subjectivity associated with 
this) and thus offers great promise of generalisation and scalability to phenotype identification for RA and other 
rheumatic diseases.  
The findings of this work demonstrate how machine learning methods can be utilized to create reliable disease 
phenotypes in EHRs. This method may be particularly valuable for large population-based research cohorts like UK 
Biobank [37][38], USA eMERGE network[39][40][41], to give simple algorithms with good performance that are 
transparent and easy to apply. This paper has also compared the data-driven methods with the two existing RA 
algorithms available for RA research using UK datasets, so offers a comparison of performance that can be used by 
researchers to decide which algorithm is most appropriate to their research. 
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Table 1: The performance of algorithms given worst case/best case assumptions 
 
(a) Data mining algorithm 
  Outpatient data (Cellma- ABMU)   
  RA Not RA No data 
GP data RA 1323 396 2560 
 Not RA 265 10084 459727 
 No data 138 1087  
 Worst case* 
Sensitivity 80 %, Specificity 99 % 
 Best case** 
Sensitivity 93 %, Specificity 99 % 
 
 Positive predictive value 30 %  Positive predictive value 90.7 %  
(b) QOF criteria 
  Outpatient data(Cellma- ABMU)   
  RA Not RA No data 
GP data RA 1377 513 2851 
 Not RA 211 9967 459436 
 No data 138 1087  
 Worst case 
Sensitivity 86.7 %, Specificity 99 % 
 Best case 
Sensitivity 95 %, Specificity 99 % 
 
 Positive predictive value 29 %  Positive predictive value 89 %  
(c) Thomas paper (expert opinion) 
  Outpatient data(Cellma- ABMU)   
  RA Not RA No data 
GP data RA 1333 570 2139 
 Not RA 255 9910 460148 
 No data 138 1087  
 Worst case 
Sensitivity 83.9 %, Specificity 99 % 
 Best case 
Sensitivity 94.2 %, Specificity 99 % 
 
 Positive predictive value 28 %  Positive predictive value 88 %  
 
  *Worst case : no record in outpatients signifies not RA.  
**Best case : no record in outpatients signifies patient with RA treated elsewhere. 
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Table 2: Algorithm code definitions 
 
Predictor Description 
RARTH_COD Rheumatoid Arthritis codes as defined in the NHS Wales QOF Rheumatoid Arthritis Indicator 
Set (RA Indicator Set NHS QOF Wales, 2014) 
INTENSITY_RA A categorical variable with 5 levels, inspired in the reasoning on Thomas et al (2008) work to 
define intensity of rheumatoid conditions:  
- Class 1 is the most severe diagnosis of rheumatoid arthritis and includes sero-positive 
rheumatoid arthritis.   
- Class 2 contains codes related to classification of rheumatoid arthritis.  
- Class 3 contains conditions that are related to rheumatoid arthritis, such as 
rheumatoid nodule.  
- Class 4 identifies patients that have sero-negetive rheumatoid arthritis. 
- The final class is class 9 and identifies patients who do not have any history of 
rheumatoid arthritis. 
ALTERNATIVE_RA Alternative arthropathy Read codes inspired in the reasoning in Thomas et al (2008).   
PSORIATIC_CD Psoriatic Arthritis Read codes 
PREDNISOLONE Read codes related to different dosage of Prednisolone. Prednisolone is an corticosteroid 
drug for controlling a local flare in a joint, which is used effectively in combination with other 
drugs (Ter Wee et al., 2014). 
METHOTREXATE_CD Disease-modifying Antirheumatic Drugs (DMARDs) grouped by their active ingredient- 
methotrexate, 
SULPHASALAZINE_CD DMARDs grouped by their active ingredient-sulphasalazine 
LEFLUNOMIDE_CD DMARDs grouped by their active ingredient-leflunomide 
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Figure legends 
Figure 1. RA phenotyping model: (Left) C5.0 decision tree. The value of a variable is the number of its occurrence. At 
each final node, RA=1 indicates classification for positive RA and RA=0 negative classified for RA. (Right) Decision 
rules generated from the C5.0 decision tree. 
Figure 2: Prevalence of RA for 2000-2010 in the ABMU region, Wales, UK 
Caption of Supplemental file 
Aggregated Read Codes Used in QoF Criteria, Thomas et al’s Model and Data-Driven Model 
 
 
